Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2024

Open Access 01-12-2024 | Solid Tumor | Review

Non-coding RNAs as potential therapeutic targets for receptor tyrosine kinase signaling in solid tumors: current status and future directions

Authors: Aysan Moeinafshar, Mohammad Nouri, Nima Shokrollahi, Mahdi Masrour, Amirmohammad Behnam, Sahand Tehrani Fateh, Hossein Sadeghi, Mohammad Miryounesi, Mohammad-Reza Ghasemi

Published in: Cancer Cell International | Issue 1/2024

Login to get access

Abstract

This review article presents an in-depth analysis of the current state of research on receptor tyrosine kinase regulatory non-coding RNAs (RTK-RNAs) in solid tumors. RTK-RNAs belong to a class of non-coding RNAs (nc-RNAs) responsible for regulating the expression and activity of receptor tyrosine kinases (RTKs), which play a critical role in cancer development and progression. The article explores the molecular mechanisms through which RTK-RNAs modulate RTK signaling pathways and highlights recent advancements in the field. This include the identification of potential new RTK-RNAs and development of therapeutic strategies targeting RTK-RNAs. While the review discusses promising results from a variety of studies, encompassing in vitro, in vivo, and clinical investigations, it is important to acknowledge the challenges and limitations associated with targeting RTK-RNAs for therapeutic applications. Further studies involving various cancer cell lines, animal models, and ultimately, patients are necessary to validate the efficacy of targeting RTK-RNAs. The specificity of ncRNAs in targeting cellular pathways grants them tremendous potential, but careful consideration is required to minimize off-target effects, the article additionally discusses the potential clinical applications of RTK-RNAs as biomarkers for cancer diagnosis, prognosis, and treatment. In essence, by providing a comprehensive overview of the current understanding of RTK-RNAs in solid tumors, this review emphasizes their potential as therapeutic targets for cancer while acknowledging the associated challenges and limitations.
Literature
1.
2.
3.
Aveic S, Tonini GP. Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy? Cancer Cell Int. 2016;16:62.PubMedPubMedCentralCrossRef
4.
Huang PH, Xu AM, White FM. Oncogenic EGFR signaling networks in glioma. Sci Signal. 2009;2(87): re6.PubMedCrossRef
5.
Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets. 2012;12(3):197–209.PubMedPubMedCentralCrossRef
6.
Mabeta P, Steenkamp V. The VEGF/VEGFR axis revisited: implications for cancer therapy. Int J Mol Sci. 2022;23(24):14485.CrossRef
7.
Lacal PM, Graziani G. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors. Pharmacol Res. 2018;136:97–107.PubMedCrossRef
8.
Zou X, Tang XY, Qu ZY, Sun ZW, Ji CF, Li YJ, et al. Targeting the PDGF/PDGFR signaling pathway for cancer therapy: a review. Int J Biol Macromol. 2022;202:539–57.PubMedCrossRef
9.
Sheikh E, Tran T, Vranic S, Levy A, Bonfil RD. Role and significance of c-KIT receptor tyrosine kinase in cancer: a review. Bosn J Basic Med Sci. 2022;22(5):683–98.PubMedPubMedCentral
10.
11.
Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17:1–13.CrossRef
12.
Ebrahimi N, Fardi E, Ghaderi H, Palizdar S, Khorram R, Vafadar R, et al. Receptor tyrosine kinase inhibitors in cancer. Cell Mol Life Sci. 2023;80(4):104.PubMedCrossRef
13.
14.
15.
16.
Mirzaei S, Gholami MH, Hushmandi K, Hashemi F, Zabolian A, Canadas I, et al. The long and short non-coding RNAs modulating EZH2 signaling in cancer. J Hematol Oncol. 2022;15(1):18.PubMedPubMedCentralCrossRef
17.
Zeng X, Xiao J, Bai X, Liu Y, Zhang M, Liu J, et al. Research progress on the circRNA/lncRNA–miRNA–mRNA axis in gastric cancer. Pathol Res Pract. 2022;238: 154030.PubMedCrossRef
18.
Chen B, Dragomir MP, Yang C, Li Q, Horst D, Calin GA, et al. Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduct Target Ther. 2022;7(1):121.PubMedPubMedCentralCrossRef
19.
20.
21.
Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev. 2018;18(1):5–18.CrossRef
22.
Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173(2):321–37.PubMedPubMedCentralCrossRef
23.
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54.PubMedCrossRef
24.
25.
Menigatti M, Staiano T, Manser CN, Bauerfeind P, Komljenovic A, Robinson M, et al. Epigenetic silencing of monoallelically methylated miRNA loci in precancerous colorectal lesions. Oncogenesis. 2013;2(7): e56.PubMedPubMedCentralCrossRef
26.
27.
de Kock L, Rivera B, Revil T, Thorner P, Goudie C, Bouron-Dal Soglio D, et al. Sequencing of DICER1 in sarcomas identifies biallelic somatic DICER1 mutations in an adult-onset embryonal rhabdomyosarcoma. Br J Cancer. 2017;116(12):1621–6.PubMedPubMedCentralCrossRef
28.
29.
Donzelli S, Cioce M, Muti P, Strano S, Yarden Y, Blandino G. MicroRNAs: non-coding fine tuners of receptor tyrosine kinase signalling in cancer. Semin Cell Dev Biol. 2016;50:133–42.PubMedCrossRef
30.
Jiang Z, Jiang C, Yu C, Fang J. MicroRNA-208b inhibits human osteosarcoma progression by targeting ROR2. Tumour Biol. 2017;39(6):1010428317705751.PubMedCrossRef
31.
Tao Y, Yang S, Wu Y, Fang X, Wang Y, Song Y, et al. MicroRNA-216a inhibits the metastasis of gastric cancer cells by targeting JAK2/STAT3-mediated EMT process. Oncotarget. 2017;8(51):88870–81.PubMedPubMedCentralCrossRef
32.
Li WJ, Wang Y, Liu R, Kasinski AL, Shen H, Slack FJ, et al. MicroRNA-34a: potent tumor suppressor, cancer stem cell inhibitor, and potential anticancer therapeutic. Front Cell Dev Biol. 2021;9: 640587.PubMedCrossRef
33.
Li C, Wang Y, Lu S, Zhang Z, Meng H, Liang L, et al. MiR-34a inhibits colon cancer proliferation and metastasis by inhibiting platelet-derived growth factor receptor α. Mol Med Rep. 2015;12(5):7072–8.PubMedCrossRef
34.
Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S, Caplen NJ. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat. 2011;130(2):663–79.PubMedPubMedCentralCrossRef
35.
Wei B, Huang QY, Huang SR, Mai W, Zhong XG. MicroRNA-34a attenuates the proliferation, invasion and metastasis of gastric cancer cells via downregulation of MET. Mol Med Rep. 2015;12(4):5255–61.PubMedCrossRef
36.
Xiong R, Sun XX, Wu HR, Xu GW, Wang GX, Sun XH, et al. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance. Thorac Cancer. 2020;11(1):156–65.PubMedCrossRef
37.
Yamamura S, Saini S, Majid S, Hirata H, Ueno K, Deng G, et al. MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS ONE. 2012;7(1): e29722.PubMedPubMedCentralCrossRef
38.
Shabani N, Razaviyan J, Paryan M, Tavangar SM, Azizi F, Mohammadi-Yeganeh S, et al. Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC. Hum Pathol. 2018;79:212–21.PubMedCrossRef
39.
Shabani N, Sheikholeslami S, Paryan M, Zarif Yeganeh M, Tavangar SM, Azizi F, et al. An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients. J Cell Physiol. 2020;235(2):1366–73.PubMedCrossRef
40.
Lim D, Cho JG, Yun E, Lee A, Ryu HY, Lee YJ, et al. MicroRNA 34a-AXL axis regulates vasculogenic mimicry formation in breast cancer Cells. Genes. 2020;12(1):9.PubMedPubMedCentralCrossRef
41.
Mohammady M, Ghetmiri SI, Baharizade M, Morowvat MH, Torabi S. Expanding the biotherapeutics realm via miR-34a: “potent clever little” agent in breast cancer therapy. Curr Pharm Biotechnol. 2019;20(8):665–73.PubMedCrossRef
42.
Imani S, Zhang X, Hosseinifard H, Fu S, Fu J. The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(14):23177–87.PubMedPubMedCentralCrossRef
43.
Han TY, Hou LS, Li JX, Huan ML, Zhou SY, Zhang BL. Bone targeted miRNA delivery system for miR-34a with enhanced anti-tumor efficacy to bone-associated metastatic breast cancer. Int J Pharm. 2023;635: 122755.PubMedCrossRef
44.
Xie X, Chen Y, Chen Z, Feng Y, Wang J, Li T, et al. Polymeric hybrid nanomicelles for cancer theranostics: an efficient and precise anticancer strategy for the codelivery of doxorubicin/miR-34a and magnetic resonance Imaging. ACS Appl Mater Interfaces. 2019;11(47):43865–78.PubMedCrossRef
45.
Wang S, Cao M, Deng X, Xiao X, Yin Z, Hu Q, et al. Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy. Adv Healthc Mater. 2015;4(2):281–90.PubMedCrossRef
46.
Zhang H, Li Y, Rao F, Liufu C, Wang Y, Chen Z. A novel UTMD system facilitating nucleic acid delivery into MDA-MB-231 cells. Biosci Rep. 2020;40(2): BSR20192573.PubMedPubMedCentralCrossRef
47.
Wang J, Feng W, Dong Y, Mao X, Guo F, Luo F. MicroRNA-495 regulates human gastric cancer cell apoptosis and migration through Akt and mTOR signaling. Oncol Rep. 2018;40(6):3654–62.PubMed
48.
Li N, Han M, Zhou N, Tang Y, Tang XS. MicroRNA-495 confers increased sensitivity to chemotherapeutic agents in gastric cancer via the mammalian target of rapamycin (mTOR) signaling pathway by interacting with human epidermal growth factor receptor 2 (ERBB2). Med Sci Monit. 2018;24:5960–72.PubMedPubMedCentralCrossRef
49.
Cheng C, Qin Y, Zhi Q, Wang J, Qin C. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol. 2018;107(Pt B):2620–9.PubMedCrossRef
50.
Cao W, Yang W, Fan R, Li H, Jiang J, Geng M, et al. miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumour Biol. 2014;35(2):1287–95.PubMedCrossRef
51.
Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem. 2009;284(9):5731–41.PubMedCrossRef
52.
Kong X, Li G, Yuan Y, He Y, Wu X, Zhang W, et al. MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS ONE. 2012;7(8): e41523.PubMedPubMedCentralCrossRef
53.
Cui YX, Bradbury R, Flamini V, Wu B, Jordan N, Jiang WG. MicroRNA-7 suppresses the homing and migration potential of human endothelial cells to highly metastatic human breast cancer cells. Br J Cancer. 2017;117(1):89–101.PubMedPubMedCentralCrossRef
54.
Lee KM, Choi EJ, Kim IA. microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol. 2011;101(1):171–6.PubMedCrossRef
55.
Xu N, Lian YJ, Dai X, Wang YJ. miR-7 increases cisplatin sensitivity of gastric cancer cells through suppressing mTOR. Technol Cancer Res Treat. 2017;16(6):1022–30.PubMedPubMedCentralCrossRef
56.
Zhao X, Dou W, He L, Liang S, Tie J, Liu C, et al. MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene. 2013;32(11):1363–72.PubMedCrossRef
57.
Lin J, Liu Z, Liao S, Li E, Wu X, Zeng W. Elevated microRNA-7 inhibits proliferation and tumor angiogenesis and promotes apoptosis of gastric cancer cells via repression of Raf-1. Cell Cycle. 2020;19(19):2496–508.PubMedPubMedCentralCrossRef
58.
Expression of Concern. Elevated microRNA-7 inhibits proliferation and tumor angiogenesis and promotes apoptosis of gastric cancer cells via repression of Raf-1. Cell Cycle. 2021;20(24):2672.CrossRef
59.
Ye T, Yang M, Huang D, Wang X, Xue B, Tian N, et al. MicroRNA-7 as a potential therapeutic target for aberrant NF-κB-driven distant metastasis of gastric cancer. J Exp Clin Cancer Res. 2019;38(1):55.PubMedPubMedCentralCrossRef
60.
Gu DN, Huang Q, Tian L. The molecular mechanisms and therapeutic potential of microRNA-7 in cancer. Expert Opin Ther Targets. 2015;19(3):415–26.PubMedCrossRef
61.
Zhao JG, Men WF, Tang J. MicroRNA-7 enhances cytotoxicity induced by gefitinib in non-small cell lung cancer via inhibiting the EGFR and IGF1R signalling pathways. Contemp Oncol (Pozn). 2015;19(3):201–6.PubMed
62.
Cao Q, Mao ZD, Shi YJ, Chen Y, Sun Y, Zhang Q, et al. MicroRNA-7 inhibits cell proliferation, migration and invasion in human non-small cell lung cancer cells by targeting FAK through ERK/MAPK signaling pathway. Oncotarget. 2016;7(47):77468–81.PubMedPubMedCentralCrossRef
63.
Kogo R, Mimori K, Tanaka F, Komune S, Mori M. Clinical significance of miR-146a in gastric cancer cases. Clin Cancer Res. 2011;17(13):4277–84.PubMedCrossRef
64.
Zhou N, Qu Y, Xu C, Tang Y. Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2. Exp Ther Med. 2016;11(2):625–30.PubMedCrossRef
65.
Chen Y, Zhou B, Xu L, Fan H, Xie J, Wang D. MicroRNA-146a promotes gastric cancer cell apoptosis by targeting transforming growth factor β-activated kinase 1. Mol Med Rep. 2017;16(1):755–63.PubMedPubMedCentralCrossRef
66.
Jiang P, Liang B, Zhang Z, Fan B, Zeng L, Zhou Z, et al. MicroRNA-146a-5p induces cell cycle arrest and enhances apoptosis in gastric cancer via targeting CDC14A. Front Cell Dev Biol. 2023;11:1181628.PubMedPubMedCentralCrossRef
67.
Hou Z, Xie L, Yu L, Qian X, Liu B. MicroRNA-146a is down-regulated in gastric cancer and regulates cell proliferation and apoptosis. Med Oncol. 2012;29(2):886–92.PubMedCrossRef
68.
Yao Q, Tu C, Lu D, Zou Y, Liu H, Zhang S. Clinicopathological significance of the microRNA-146a/WASP-family verprolin-homologous protein-2 axis in gastric cancer. Cancer Sci. 2017;108(7):1285–92.PubMedPubMedCentralCrossRef
69.
Luo Z, Li X, Zhao Z, Yang X, Xiao S, Zhou Y. MicroRNA-146a affects the chemotherapeutic sensitivity and prognosis of advanced gastric cancer through the regulation of LIN52. Oncol Lett. 2017;13(3):1386–92.PubMedCrossRef
70.
Lian S, Park JS, Xia Y, Nguyen TT, Joo YE, Kim KK, et al. MicroRNA-375 functions as a tumor-suppressor gene in gastric cancer by targeting recepteur d’Origine Nantais. Int J Mol Sci. 2016;17(10):1633.PubMedPubMedCentralCrossRef
71.
Yan XL, Luo QY, Zhou SN, Pan WT, Zhang L, Yang DJ, et al. MicroRNA-375 reverses the expression of PD-L1 by inactivating the JAK2/STAT3 signaling pathways in gastric cancer. Clin Res Hepatol Gastroenterol. 2021;45(5): 101574.PubMedCrossRef
72.
Chen B, Guo S, Yu Z, Feng Y, Hui L. Downregulation of microRNA-375, combined with upregulation of its target gene Janus kinase 2, predicts unfavorable prognosis in patients with gastric cancer. Int J Clin Exp Pathol. 2017;10(11):11106–13.PubMedPubMedCentral
73.
Li Y, Jiang Q, Xia N, Yang H, Hu C. Decreased expression of microRNA-375 in nonsmall cell lung cancer and its clinical significance. J Int Med Res. 2012;40(5):1662–9.PubMedCrossRef
74.
Chen LJ, Li XY, Zhao YQ, Liu WJ, Wu HJ, Liu J, et al. Down-regulated microRNA-375 expression as a predictive biomarker in non-small cell lung cancer brain metastasis and its prognostic significance. Pathol Res Pract. 2017;213(8):882–8.PubMedCrossRef
75.
Yu H, Jiang L, Sun C, Li Guo L, Lin M, Huang J, et al. Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. Gene. 2014;534(1):60–5.PubMedCrossRef
76.
Chen WJ, Gan TQ, Qin H, Huang SN, Yang LH, Fang YY, et al. Implication of downregulation and prospective pathway signaling of microRNA-375 in lung squamous cell carcinoma. Pathol Res Pract. 2017;213(4):364–72.PubMedCrossRef
77.
78.
Chen Z, Gao YJ, Hou RZ, Ding DY, Song DF, Wang DY, et al. MicroRNA-206 facilitates gastric cancer cell apoptosis and suppresses cisplatin resistance by targeting MAPK2 signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(1):171–80.PubMed
79.
Zheng Z, Yan D, Chen X, Huang H, Chen K, Li G, et al. MicroRNA-206: effective inhibition of gastric cancer progression through the c-Met pathway. PLoS ONE. 2015;10(7): e0128751.PubMedPubMedCentralCrossRef
80.
Zhou Y, Cai W, Lu H. Overexpression of microRNA-145 enhanced docetaxel sensitivity in breast cancer cells via inactivation of protein kinase B gamma-mediated phosphoinositide 3-kinase -protein kinase B pathway. Bioengineered. 2022;13(4):11310–20.PubMedPubMedCentralCrossRef
81.
Zheng M, Sun X, Li Y, Zuo W. MicroRNA-145 inhibits growth and migration of breast cancer cells through targeting oncoprotein ROCK1. Tumour Biol. 2016;37(6):8189–96.PubMedCrossRef
82.
Kim SJ, Oh JS, Shin JY, Lee KD, Sung KW, Nam SJ, et al. Development of microRNA-145 for therapeutic application in breast cancer. J Control Release. 2011;155(3):427–34.PubMedCrossRef
83.
Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, Yarden Y, Domany E, Blandino G. The locus of microRNA-10b: a critical target for breast cancer insurgence and dissemination. Cell Cycle. 2013;12(15):2371–5.PubMedPubMedCentralCrossRef
84.
Han M, Wang F, Gu Y, Pei X, Guo G, Yu C, et al. MicroRNA-21 induces breast cancer cell invasion and migration by suppressing smad7 via EGF and TGF-β pathways. Oncol Rep. 2016;35(1):73–80.PubMedCrossRef
85.
Fang H, Xie J, Zhang M, Zhao Z, Wan Y, Yao Y. miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN. Am J Transl Res. 2017;9(3):953–61.PubMedPubMedCentral
86.
Chen J, Wang X. MicroRNA-21 in breast cancer: diagnostic and prognostic potential. Clin Transl Oncol. 2014;16(3):225–33.PubMedCrossRef
87.
Lai CY, Yeh KY, Lin CY, Hsieh YW, Lai HH, Chen JR, et al. MicroRNA-21 plays multiple oncometabolic roles in the process of NAFLD-related hepatocellular carcinoma via PI3K/AKT, TGF-β, and STAT3 signaling. Cancers. 2021;13(5):940.PubMedPubMedCentralCrossRef
88.
Bharali D, Banerjee BD, Bharadwaj M, Husain SA, Kar P. Expression analysis of microRNA-21 and microRNA-122 in hepatocellular carcinoma. J Clin Exp Hepatol. 2019;9(3):294–301.PubMedCrossRef
89.
Qu J, Yang J, Chen M, Cui L, Wang T, Gao W, et al. MicroRNA-21 as a diagnostic marker for hepatocellular carcinoma: a systematic review and meta-analysis. Pak J Med Sci. 2019;35(5):1466–71.PubMedPubMedCentralCrossRef
90.
Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta. 2010;411(11–12):846–52.PubMedCrossRef
91.
Wang W, Li X, Liu C, Zhang X, Wu Y, Diao M, et al. MicroRNA-21 as a diagnostic and prognostic biomarker of lung cancer: a systematic review and meta-analysis. Biosci Rep. 2022;42(5):BSR0211653.CrossRef
92.
Xue X, Liu Y, Wang Y, Meng M, Wang K, Zang X, et al. MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. Oncotarget. 2016;7(51):84508–19.PubMedPubMedCentralCrossRef
93.
Xu S, Shi L. High expression of miR-155 and miR-21 in the recurrence or metastasis of non-small cell lung cancer. Oncol Lett. 2019;18(1):758–63.PubMedPubMedCentral
94.
Shao C, Yang F, Qin Z, Jing X, Shu Y, Shen H. The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis. BMC Cancer. 2019;19(1):1103.PubMedPubMedCentralCrossRef
95.
Wang J, Wang Q, Guan Y, Sun Y, Wang X, Lively K, et al. Breast cancer cell-derived microRNA-155 suppresses tumor progression via enhancing immune cell recruitment and antitumor function. J Clin Investag. 2022;132(19): e157248.CrossRef
96.
Zhang G, Zhong L, Luo H, Wang S. MicroRNA-155-3p promotes breast cancer progression through down-regulating CADM1. Onco Targets Ther. 2019;12:7993–8002.PubMedPubMedCentralCrossRef
97.
Hosseini Mojahed F, Aalami AH, Pouresmaeil V, Amirabadi A, Qasemi Rad M, Sahebkar A. Clinical evaluation of the diagnostic role of microRNA-155 in breast cancer. Int J Genomics. 2020;2020:9514831.PubMedPubMedCentralCrossRef
98.
Li D, Liu X, Lin L, Hou J, Li N, Wang C, et al. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem. 2011;286(42):36677–85.PubMedPubMedCentralCrossRef
99.
Ning S, Liu H, Gao B, Wei W, Yang A, Li J, et al. miR-155, miR-96 and miR-99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma. Oncol Lett. 2019;18(3):3381–7.PubMedPubMedCentral
100.
Cai C, Xie Y, Wu L, Chen X, Liu H, Zhou Y, et al. PLGA-based dual targeted nanoparticles enhance miRNA transfection efficiency in hepatic carcinoma. Sci Rep. 2017;7:46250.PubMedPubMedCentralCrossRef
101.
Sheng L, He P, Yang X, Zhou M, Feng Q. miR-612 negatively regulates colorectal cancer growth and metastasis by targeting AKT2. Cell Death Dis. 2015;6(7): e1808.PubMedPubMedCentralCrossRef
102.
Zhu SH, He XC, Wang L. Correlation analysis of miR-200b, miR-200c, and miR-141 with liver metastases in colorectal cancer patients. Eur Rev Med Pharmacol Sci. 2017;21(10):2357–63.PubMed
103.
Chen X, Zeng K, Xu M, Liu X, Hu X, Xu T, et al. P53-induced miR-1249 inhibits tumor growth, metastasis, and angiogenesis by targeting VEGFA and HMGA2. Cell Death Dis. 2019;10(2):131.PubMedPubMedCentralCrossRef
104.
Zhou Q, Zhu Y, Wei X, Zhou J, Chang L, Sui H, et al. MiR-590-5p inhibits colorectal cancer angiogenesis and metastasis by regulating nuclear factor 90/vascular endothelial growth factor A axis. Cell Death Dis. 2016;7(10): e2413.PubMedPubMedCentralCrossRef
105.
Xu Z, Zhu C, Chen C, Zong Y, Feng H, Liu D, et al. CCL19 suppresses angiogenesis through promoting miR-206 and inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A pathway in colorectal cancer. Cell Death Dis. 2018;9(10):974.PubMedPubMedCentralCrossRef
106.
Zeng Z, Li Y, Pan Y, Lan X, Song F, Sun J, et al. Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat Commun. 2018;9(1):5395.PubMedPubMedCentralCrossRef
107.
Qian X, Yu J, Yin Y, He J, Wang L, Li Q, et al. MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle. 2013;12(9):1385–94.PubMedPubMedCentralCrossRef
108.
Zhang Y, Wang X, Xu B, Wang B, Wang Z, Liang Y, et al. Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep. 2013;30(4):1976–84.PubMedCrossRef
109.
Tsang WP, Kwok TT. The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. Carcinogenesis. 2009;30(6):953–9.PubMedCrossRef
110.
Han HB, Gu J, Zuo HJ, Chen ZG, Zhao W, Li M, et al. Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer. J Pathol. 2012;226(3):544–55.PubMedCrossRef
111.
Wang MJ, Li Y, Wang R, Wang C, Yu YY, Yang L, et al. Downregulation of microRNA-124 is an independent prognostic factor in patients with colorectal cancer. Int J Colorectal Dis. 2013;28(2):183–9.PubMedCrossRef
112.
Zhang Z, Wang J, Cheng J, Yu X. Effects of miR-126 on the STAT3 signaling pathway and the regulation of malignant behavior in lung cancer cells. Oncol Lett. 2018;15(6):8412–6.PubMedPubMedCentral
113.
Shi H, Bi H, Sun X, Dong H, Jiang Y, Mu H, et al. Antitumor effects of tubeimoside-1 in NCI-H1299 cells are mediated by microRNA-126-5p-induced inactivation of VEGF-A/VEGFR-2/ERK signaling pathway. Mol Med Rep. 2018;17(3):4327–36.PubMedPubMedCentral
114.
Jia Z, Zhang Y, Xu Q, Guo W, Guo A. miR-126 suppresses epithelial-to-mesenchymal transition and metastasis by targeting PI3K/AKT/Snail signaling of lung cancer cells. Oncol Lett. 2018;15(5):7369–75.PubMedPubMedCentral
115.
Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15(2):261–71.PubMedPubMedCentralCrossRef
116.
Hou L, Luo P, Ma Y, Jia C, Yu F, Lv Z, et al. MicroRNA-125a-3p downregulation correlates with tumorigenesis and poor prognosis in patients with non-small cell lung cancer. Oncol Lett. 2017;14(4):4441–8.PubMedPubMedCentralCrossRef
117.
Huang H, Huang J, Yao J, Li N, Yang Z. miR-125a regulates HAS1 and inhibits the proliferation, invasion and metastasis by targeting STAT3 in non-small cell lung cancer cells. J Cell Biochem. 2020;121(5–6):3197–207.PubMedCrossRef
118.
Yagishita S, Fujita Y, Kitazono S, Ko R, Nakadate Y, Sawada T, et al. Chemotherapy-regulated microRNA-125-HER2 pathway as a novel therapeutic target for trastuzumab-mediated cellular cytotoxicity in small cell lung cancer. Mol Cancer Ther. 2015;14(6):1414–23.PubMedCrossRef
119.
Khan P, Ebenezer NS, Siddiqui JA, Maurya SK, Lakshmanan I, Salgia R, et al. MicroRNA-1: diverse role of a small player in multiple cancers. Semin Cell Dev Biol. 2022;124:114–26.PubMedCrossRef
120.
Qu W, Chen X, Wang J, Lv J, Yan D. MicroRNA-1 inhibits ovarian cancer cell proliferation and migration through c-Met pathway. Clin Chim Acta. 2017;473:237–44.PubMedCrossRef
121.
Migliore C, Martin V, Leoni VP, Restivo A, Atzori L, Petrelli A, et al. MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res. 2012;18(3):737–47.PubMedCrossRef
122.
Reid JF, Sokolova V, Zoni E, Lampis A, Pizzamiglio S, Bertan C, et al. miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res. 2012;10(4):504–15.PubMedCrossRef
123.
Jiang S, Zhao C, Yang X, Li X, Pan Q, Huang H, et al. miR-1 suppresses the growth of esophageal squamous cell carcinoma in vivo and in vitro through the downregulation of MET, cyclin D1 and CDK4 expression. Int J Mol Med. 2016;38(1):113–22.PubMedPubMedCentralCrossRef
124.
Koshizuka K, Hanazawa T, Fukumoto I, Kikkawa N, Matsushita R, Mataki H, et al. Dual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma. J Hum Genet. 2017;62(1):113–21.PubMedCrossRef
125.
Novello C, Pazzaglia L, Cingolani C, Conti A, Quattrini I, Manara MC, et al. miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol. 2013;42(2):667–75.PubMedCrossRef
126.
Chang YS, Chen WY, Yin JJ, Sheppard-Tillman H, Huang J, Liu YN. EGF receptor promotes prostate cancer bone metastasis by downregulating miR-1 and activating TWIST1. Cancer Res. 2015;75(15):3077–86.PubMedPubMedCentralCrossRef
127.
Chiu KL, Lin YS, Kuo TT, Lo CC, Huang YK, Chang HF, et al. ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis. Oncotarget. 2017;8(29):47365–78.PubMedPubMedCentralCrossRef
128.
Han C, Zhou Y, An Q, Li F, Li D, Zhang X, et al. MicroRNA-1 (miR-1) inhibits gastric cancer cell proliferation and migration by targeting MET. Tumour Biol. 2015;36(9):6715–23.PubMedCrossRef
129.
Yan D, Dong Xda E, Chen X, Wang L, Lu C, Wang J, et al. MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem. 2009;284(43):29596–604.PubMedPubMedCentralCrossRef
130.
131.
Baboci L, Capolla S, Di Cintio F, Colombo F, Mauro P, Dal Bo M, et al. The dual role of the liver in nanomedicine as an actor in the elimination of nanostructures or a therapeutic target. J Oncol. 2020;2020:4638192.PubMedPubMedCentralCrossRef
132.
Alehossein P, Taheri M, Tayefeh Ghahremani P, Dakhlallah D, Brown CM, Ishrat T, et al. Transplantation of exercise-induced extracellular vesicles as a promising therapeutic approach in ischemic stroke. Transl Stroke Res. 2023;14(2):211–37.PubMedCrossRef
133.
Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu C-G, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Can Res. 2007;67(13):6092–9.CrossRef
134.
Tsai W-C, Hsu PW-C, Lai T-C, Chau G-Y, Lin C-W, Chen C-M, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. 2009;49(5):1571–82.PubMedCrossRef
135.
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2):647–58.PubMedCrossRef
136.
Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, et al. Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res. 2008;14(2):419–27.PubMedPubMedCentralCrossRef
137.
Panebianco F, Climent M, Malvindi MA, Pompa PP, Bonetti P, Nicassio F. Delivery of biologically active miR-34a in normal and cancer mammary epithelial cells by synthetic nanoparticles. Nanomed Nanotechnol Biol Med. 2019;19:95–105.CrossRef
138.
Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Can Res. 2010;70(14):5923–30.CrossRef
139.
Kasinski AL, Kelnar K, Stahlhut C, Orellana E, Zhao J, Shimer E, et al. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene. 2015;34(27):3547–55.PubMedCrossRef
140.
Cortez MA, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin GA, et al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther. 2014;22(8):1494–503.PubMedPubMedCentralCrossRef
141.
Beg MS, Brenner AJ, Sachdev J, Borad M, Kang Y-K, Stoudemire J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017;35:180–8.PubMedCrossRef
142.
Hong DS, Kang Y-K, Borad M, Sachdev J, Ejadi S, Lim HY, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020;122(11):1630–7.PubMedPubMedCentralCrossRef
143.
Wu Y, Crawford M, Mao Y, Lee RJ, Davis IC, Elton TS, et al. Therapeutic delivery of MicroRNA-29b by cationic lipoplexes for lung cancer. Mol Ther Nucleic Acids. 2013;2(4): e84.PubMedPubMedCentralCrossRef
144.
van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol. 2017;18(10):1386–96.PubMedCrossRef
145.
Hsieh TH, Hsu CY, Tsai CF, Long CY, Chai CY, Hou MF, et al. miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis. Oncotarget. 2015;6(1):494–509.PubMedCrossRef
146.
Hayward SL, Francis DM, Kholmatov P, Kidambi S. Targeted delivery of microRNA125a-5p by engineered lipid nanoparticles for the treatment of HER2 positive metastatic breast cancer. J Biomed Nanotechnol. 2016;12(3):554–68.PubMedCrossRef
147.
Deng X, Cao M, Zhang J, Hu K, Yin Z, Zhou Z, et al. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Biomaterials. 2014;35(14):4333–44.PubMedCrossRef
148.
149.
Zhi F, Dong H, Jia X, Guo W, Lu H, Yang Y, et al. Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance in vitro. PLoS ONE. 2013;8(3): e60034.PubMedPubMedCentralCrossRef
150.
Yu Y, Yao Y, Yan H, Wang R, Zhang Z, Sun X, et al. A tumor-specific microRNA recognition system facilitates the accurate targeting to tumor cells by magnetic nanoparticles. Mol Ther Nucleic Acids. 2016;5(5): e318.PubMedPubMedCentralCrossRef
151.
Kim HK, Fuchs G, Wang S, Wei W, Zhang Y, Park H, et al. A transfer-RNA-derived small RNA regulates ribosome biogenesis. Nature. 2017;552(7683):57–62.PubMedPubMedCentralCrossRef
152.
Iwasaki YW, Siomi MC, Siomi H. PIWI-interacting RNA: its biogenesis and functions. Annu Rev Biochem. 2015;84:405–33.PubMedCrossRef
153.
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37.PubMedCrossRef
154.
155.
Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47–62.PubMedCrossRef
156.
Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458(7235):223–7.PubMedPubMedCentralCrossRef
157.
158.
Hong Q, Li O, Zheng W, Xiao W-Z, Zhang L, Wu D, et al. LncRNA HOTAIR regulates HIF-1α/AXL signaling through inhibition of miR-217 in renal cell carcinoma. Cell Death Dis. 2017;8(5): e2772.PubMedPubMedCentralCrossRef
159.
Li Q, Wang X, Jiang N, Xie X, Liu N, Liu J, et al. Exosome-transmitted linc00852 associated with receptor tyrosine kinase AXL dysregulates the proliferation and invasion of osteosarcoma. Cancer Med. 2020;9(17):6354–66.PubMedPubMedCentralCrossRef
160.
Yu X, Lin Q, Liu F, Yang F, Mao J, Chen X. LncRNA TMPO-AS1 facilitates the proliferation and metastasis of NSCLC cells by up-regulating ERBB2 via sponging miR-204-3p. Int J Immunopathol Pharmacol. 2020;34:2058738420958947.PubMedPubMedCentralCrossRef
161.
Zhang H, Liao Z, Liu F, Su C, Zhu H, Li Y, et al. Long noncoding RNA HULC promotes hepatocellular carcinoma progression. Aging (Albany NY). 2019;11(20):9111.PubMedCrossRef
162.
Yang L, Cao M, Zhang J, Li X, Sun Q. LncRNA XIST modulates HIF-1A/AXL signaling pathway by inhibiting miR-93-5p in colorectal cancer. Mol Genet Genomic Med. 2020;8(4): e1112.PubMedPubMedCentralCrossRef
163.
Zhang R, Wang Z, Yu Q, Shen J, He W, Zhou D, et al. Atractylenolide II reverses the influence of lncRNA XIST/miR-30a-5p/ROR1 axis on chemo-resistance of colorectal cancer cells. J Cell Mol Med. 2019;23(5):3151–65.PubMedPubMedCentralCrossRef
164.
Yue B, Cai D, Liu C, Fang C, Yan D. Linc00152 functions as a competing endogenous RNA to confer oxaliplatin resistance and holds prognostic values in colon cancer. Mol Ther. 2016;24(12):2064–77.PubMedPubMedCentralCrossRef
165.
Vennin C, Spruyt N, Dahmani F, Julien S, Bertucci F, Finetti P, et al. H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget. 2015;6(30):29209.PubMedPubMedCentralCrossRef
166.
Bi S, Wang C, Li Y, Zhang W, Zhang J, Lv Z, et al. LncRNA-MALAT1-mediated Axl promotes cell invasion and migration in human neuroblastoma. Tumor Biol. 2017;39(5):1010428317699796.CrossRef
167.
Kawasaki Y, Miyamoto M, Oda T, Matsumura K, Negishi L, Nakato R, et al. The novel lnc RNA CALIC upregulates AXL to promote colon cancer metastasis. EMBO Rep. 2019;20(8): e47052.PubMedPubMedCentralCrossRef
168.
Samimi H, Haghpanah V, Irani S, Arefian E, Sohi AN, Fallah P, et al. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor “BI-847325” on anaplastic thyroid carcinoma. DARU J Pharm Sci. 2019;27:1–7.CrossRef
169.
Li C, Wang S, Xing Z, Lin A, Liang K, Song J, et al. A ROR1–HER3–lncRNA signalling axis modulates the Hippo–YAP pathway to regulate bone metastasis. Nat Cell Biol. 2017;19(2):106–19.PubMedPubMedCentralCrossRef
170.
Drak Alsibai K, Meseure D. Tumor microenvironment and noncoding RNAs as co-drivers of epithelial–mesenchymal transition and cancer metastasis. Dev Dyn. 2018;247(3):405–31.PubMedCrossRef
171.
Yan J, Xu C, Li Y, Tang B, Xie S, Hong T, et al. Long non-coding RNA LINC00526 represses glioma progression via forming a double negative feedback loop with AXL. J Cell Mol Med. 2019;23(8):5518–31.PubMedPubMedCentralCrossRef
172.
Sas-Chen A, Aure MR, Leibovich L, Carvalho S, Enuka Y, Körner C, et al. LIMT is a novel metastasis inhibiting lnc RNA suppressed by EGF and downregulated in aggressive breast cancer. EMBO Mol Med. 2016;8(9):1052–64.PubMedPubMedCentralCrossRef
173.
174.
Wang Y, Liu Z, Yao B, Dou C, Xu M, Xue Y, et al. Long non-coding RNA TUSC7 acts a molecular sponge for miR-10a and suppresses EMT in hepatocellular carcinoma. Tumor Biol. 2016;37:11429–41.CrossRef
175.
Ding D, Zhang J, Luo Z, Wu H, Lin Z, Liang W, et al. Analysis of the lncRNA–miRNA–mRNA network reveals a potential regulatory mechanism of EGFR-TKI resistance in NSCLC. Front Genet. 2022;13: 851391.PubMedPubMedCentralCrossRef
176.
Si J, Ma Y, Lv C, Hong Y, Tan H, Yang Y. HIF1A-AS2 induces osimertinib resistance in lung adenocarcinoma patients by regulating the miR-146b-5p/IL-6/STAT3 axis. Mol Ther Nucleic Acids. 2021;26:613–24.PubMedPubMedCentralCrossRef
177.
Dong S, Qu X, Li W, Zhong X, Li P, Yang S, et al. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression. J Hematol Oncol. 2015;8(1):1–13.CrossRef
178.
Lv P, Yang S, Liu W, Qin H, Tang X, Wu F, et al. Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor-tyrosine kinase inhibitor therapy. Thorac Cancer. 2020;11(1):29–40.PubMedCrossRef
179.
Cheng N, Cai W, Ren S, Li X, Wang Q, Pan H, et al. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer. Oncotarget. 2015;6(27):23582.PubMedPubMedCentralCrossRef
180.
Takahashi S, Noro R, Seike M, Zeng C, Matsumoto M, Yoshikawa A, et al. Long non-coding RNA CRNDE is involved in resistance to EGFR tyrosine kinase inhibitor in EGFR-mutant lung cancer via eIF4A3/MUC1/EGFR signaling. Int J Mol Sci. 2021;22(8):4005.PubMedPubMedCentralCrossRef
181.
Wang S, Liu C, Lei Q, Wu Z, Miao X, Zhu D, et al. Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells. Respir Res. 2021;22(1):1–10.PubMedPubMedCentralCrossRef
182.
Zhai W, Sun Y, Guo C, Hu G, Wang M, Zheng J, et al. LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor (AR)/miRNA-143-3p signals. Cell Death Differ. 2017;24(9):1502–17.PubMedPubMedCentralCrossRef
183.
Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19(2):141–57.PubMedPubMedCentralCrossRef
184.
Li X, Liu C-X, Xue W, Zhang Y, Jiang S, Yin Q-F, et al. Coordinated circRNA biogenesis and function with NF90/NF110 in viral infection. Mol Cell. 2017;67(2):214–27.PubMedCrossRef
185.
186.
Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384–8.PubMedCrossRef
187.
Chen Y, Wu Y. Hsa_circ_0070661 inhibits cancer progression through miR-556–5p/TEK axis in lung adenocarcinoma. Cancer Biomark. 2023;37:1–13.PubMedCrossRef
188.
Li W, Wang H, Zheng Y. Circ_0001058 represses the progression of lung adenocarcinoma through governing of the miR-486-5p/TEK signaling axis. Anticancer Drugs. 2022;33(8):710–9.PubMedCrossRef
189.
Wang X, Zhu X, Zhang H, Wei S, Chen Y, Chen Y, et al. Increased circular RNA hsa_circ_0012673 acts as a sponge of miR-22 to promote lung adenocarcinoma proliferation. Biochem Biophys Res Commun. 2018;496(4):1069–75.PubMedCrossRef
190.
Pei J, Dou H, Deng X. CircFAM53B promotes the proliferation and metastasis of glioma through activating the c-MET/PI3K/AKT pathway via sponging miR-532-3p. Cell Cycle. 2022;21(5):462–76.PubMedPubMedCentralCrossRef
191.
Wang J, Li J, Duan P, Dang Y, Shi T. Circ_0001588 upregulates erbb4 to promote glioma malignant progression through sponging mir-1281. Neurotox Res. 2022;89:1–14.
192.
Zhou D, Lin X, Wang P, Yang Y, Zheng J, Zhou D. Circular RNA circ_0001162 promotes cell proliferation and invasion of glioma via the miR-936/ERBB4 axis. Bioengineered. 2021;12(1):2106–18.PubMedPubMedCentralCrossRef
193.
Jin C, Zhao J, Zhang ZP, Wu M, Li J, Liu B, et al. CircRNA EPHB4 modulates stem properties and proliferation of gliomas via sponging miR-637 and up-regulating SOX10. Mol Oncol. 2021;15(2):596–622.PubMedCrossRef
194.
Yang H, Yu G, Wang Y, Guo X. Circ_0044520 regulates the progression of laryngeal squamous cell carcinoma via the miR-338–3p/ROR2 axis. Histol Histopathol. 2022;37(6):513–26.PubMed
195.
Yejia C, Jin C, Huang S, Jinjun Y, Huang H, Dan L, et al. circRNA_0006470 promotes the proliferation and migration of gastric cancer cells by functioning as a sponge of miR-27b-3p. Neoplasma. 2021;68(6):1245.CrossRef
196.
Yang B, Teng F, Chang L, Wang J, Liu D-L, Cui Y-S, et al. Tumor-derived exosomal circRNA_102481 contributes to EGFR-TKIs resistance via the miR-30a-5p/ROR1 axis in non-small cell lung cancer. Aging (Albany NY). 2021;13(9):13264.PubMedCrossRef
197.
Chen LY, Zhi Z, Wang L, Zhao YY, Deng M, Liu YH, et al. NSD2 circular RNA promotes metastasis of colorectal cancer by targeting miR-199b-5p-mediated DDR1 and JAG1 signalling. J Pathol. 2019;248(1):103–15.PubMedCrossRef
198.
Zheng H, Fu Q, Ma K, Shi S, Fu Y. Circ_0079558 promotes papillary thyroid cancer progression by binding to miR-26b-5p to activate MET/AKT signaling. Endocr J. 2021;68(11):1247–66.PubMedCrossRef
199.
Wang S, Li Z, Zhu G, Hong L, Hu C, Wang K, et al. RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis. J Ovarian Res. 2021;14:1–17.CrossRef
200.
Deng L, Liu G, Zheng C, Zhang L, Kang Y, Yang F. Circ-LAMP1 promotes T-cell lymphoblastic lymphoma progression via acting as a ceRNA for miR-615-5p to regulate DDR2 expression. Gene. 2019;701:146–51.PubMedCrossRef
201.
Dai C, Ma Z, Si J, An G, Zhang W, Li S, et al. Hsa_circ_0007312 promotes third-generation epidermal growth factor receptor-tyrosine kinase inhibitor resistance through pyroptosis and apoptosis via the MiR-764/MAPK1 axis in lung adenocarcinoma cells. J Cancer. 2022;13(9):2798.PubMedPubMedCentralCrossRef
202.
Niu R, Li D, Chen J, Zhao W. Circ_0014235 confers Gefitinib resistance and malignant behaviors in non-small cell lung cancer resistant to Gefitinib by governing the miR-146b-5p/YAP/PD-L1 pathway. Cell Cycle. 2022;21(1):86–100.PubMedCrossRef
203.
Liu S, Jiang Z, Xiao P, Li X, Chen Y, Tang H, et al. Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p/IGF1R axis in lung adenocarcinoma cells. Cancer Sci. 2022;113(1):79–90.PubMedCrossRef
204.
Gao J, Ding C, Zhou J, Wu G, Han Z, Li J, et al. Propofol suppresses lung cancer tumorigenesis by modulating the circ-ERBB2/miR-7-5p/FOXM1 axis. Thorac Cancer. 2021;12(6):824–34.PubMedPubMedCentralCrossRef
205.
Liu Y-T, Han X-H, Xing P-Y, Hu X-S, Hao X-Z, Wang Y, et al. Circular RNA profiling identified as a biomarker for predicting the efficacy of Gefitinib therapy for non-small cell lung cancer. J Thorac Dis. 2019;11(5):1779.PubMedPubMedCentralCrossRef
206.
Wang T, Liu Z, She Y, Deng J, Zhong Y, Zhao M, et al. A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis. Cancer Lett. 2021;520:321–31.PubMedCrossRef
207.
Tan L, Huang Z, Chen Z, Chen S, Ye Y, Chen T, et al. CircRNA_001895 promotes sunitinib resistance of renal cell carcinoma through regulation of apoptosis and DNA damage repair. J Chemother. 2023;35(1):11–8.PubMedCrossRef
208.
209.
Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem. 2011;57(1):84–91.PubMedCrossRef
210.
Yang G, Wu D, Zhu J, Jiang O, Shi Q, Tian J, et al. Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1. Oncol Rep. 2013;30(2):877–89.PubMedCrossRef
211.
Zhao FL, Dou YC, Wang XF, Han DC, Lv ZG, Ge SL, et al. Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer. Mol Biol Rep. 2014;41(9):5913–22.PubMedCrossRef
212.
Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, et al. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS ONE. 2012;7(10): e47003.PubMedPubMedCentralCrossRef
213.
Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y, et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol. 2013;34(4):2175–81.PubMedCrossRef
214.
Jiang M, Li X, Quan X, Li X, Zhou B. MiR-92a family: a novel diagnostic biomarker and potential therapeutic target in human cancers. Front Mol Biosci. 2019;6:98.PubMedPubMedCentralCrossRef
215.
Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, et al. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg. 2014;259(4):735–43.PubMedCrossRef
216.
Zuo Z, Li Y, Zeng C, Xi Y, Tao H, Guo Y. Integrated analyses identify key molecules and reveal the potential mechanism of miR-182-5p/FOXO1 axis in alcoholic liver disease. Front Med. 2021;8: 767584.CrossRef
217.
Soliman SE, Elabd NS, El-Kousy SM, Awad MF. Down regulation of miR-30a-5p and miR-182-5p in gastric cancer: clinical impact and survival analysis. Biochem Biophys Rep. 2021;27: 101079.PubMedPubMedCentral
218.
Wu J, Li G, Wang Z, Yao Y, Chen R, Pu X, et al. Circulating microRNA-21 is a potential diagnostic biomarker in gastric cancer. Dis Markers. 2015;2015: 435656.PubMedPubMedCentralCrossRef
219.
Peng Q, Shen Y, Lin K, Zou L, Shen Y, Zhu Y. Comprehensive and integrative analysis identifies microRNA-106 as a novel non-invasive biomarker for detection of gastric cancer. J Transl Med. 2018;16(1):127.PubMedPubMedCentralCrossRef
220.
Cai H, Yuan Y, Hao YF, Guo TK, Wei X, Zhang YM. Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Med Oncol. 2013;30(1):452.PubMedCrossRef
221.
Farasati Far B, Vakili K, Fathi M, Yaghoobpoor S, Bhia M, Naimi-Jamal MR. The role of microRNA-21 (miR-21) in pathogenesis, diagnosis, and prognosis of gastrointestinal cancers: a review. Life Sci. 2023;316: 121340.PubMedCrossRef
222.
Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila). 2009;2(9):807–13.PubMedCrossRef
223.
Xia J, Cao T, Ma C, Shi Y, Sun Y, Wang ZP, et al. miR-7 suppresses tumor progression by directly targeting MAP3K9 in pancreatic cancer. Mol Ther Nucleic Acids. 2018;13:121–32.PubMedPubMedCentralCrossRef
224.
Ye ZQ, Zou CL, Chen HB, Jiang MJ, Mei Z, Gu DN. MicroRNA-7 as a potential biomarker for prognosis in pancreatic cancer. Dis Markers. 2020;2020:2782101.PubMedPubMedCentralCrossRef
225.
Paik WH, Song BJ, Kim HW, Kim HR, Hwang JH. MicroRNA-200c as a prognostic biomarker for pancreatic cancer. Korean J Gastroenterol. 2015;66(4):215–20.PubMedCrossRef
226.
Dong L, Hou X, Liu F, Tao H, Zhang Y, Zhao H, et al. Regulation of insulin resistance by targeting the insulin-like growth factor 1 receptor with microRNA-122-5p in hepatic cells. Cell Biol Int. 2019;43(5):553–64.PubMedCrossRef
227.
Dai M, Li L, Qin X. Clinical value of miRNA-122 in the diagnosis and prognosis of various types of cancer. Oncol Lett. 2019;17(4):3919–29.PubMedPubMedCentral
228.
Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol. 2012;56(1):167–75.PubMedCrossRef
229.
Yang JS, Li BJ, Lu HW, Chen Y, Lu C, Zhu RX, et al. Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening. Tumour Biol. 2015;36(4):3035–42.PubMedCrossRef
230.
Grimolizzi F, Monaco F, Leoni F, Bracci M, Staffolani S, Bersaglieri C, et al. Exosomal miR-126 as a circulating biomarker in non-small-cell lung cancer regulating cancer progression. Sci Rep. 2017;7(1):15277.PubMedPubMedCentralCrossRef
231.
Zhu W, Zhou K, Zha Y, Chen D, He J, Ma H, et al. Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer. PLoS ONE. 2016;11(4): e0153046.PubMedPubMedCentralCrossRef
232.
Hou B, Ishinaga H, Midorikawa K, Nakamura S, Hiraku Y, Oikawa S, et al. Let-7c inhibits migration and epithelial-mesenchymal transition in head and neck squamous cell carcinoma by targeting IGF1R and HMGA2. Oncotarget. 2018;9(10):8927–40.PubMedPubMedCentralCrossRef
233.
Dou H, Wang Y, Su G, Zhao S. Decreased plasma let-7c and miR-152 as noninvasive biomarker for non-small-cell lung cancer. Int J Clin Exp Med. 2015;8(6):9291–8.PubMedPubMedCentral
234.
Huang Y-F, Zhang Y, Fu X. Long non-coding RNA DANCR promoted non-small cell lung cancer cells metastasis via modulating of miR-1225–3p/ErbB2 signal. Eur Rev Med Pharm Sci. 2021;25(2):758–69.
235.
Du Y, Chen Y, Wu T, Fan X, Lin W, Jiang Z. miR-2682-3p antagonizes its host lncRNA-MIR137HG by interacting with the same target FUS to regulate the progression of gastric cancer. BMC Cancer. 2022;22(1):1–15.
236.
Han X, Jia Y, Chen X, Sun C, Sun J. lncRNA TINCR attenuates the proliferation and invasion, and enhances the apoptosis of cutaneous malignant melanoma cells by regulating the miR-424-5p/LATS1 axis. Oncol Rep. 2021;46(5):1–11.CrossRef
237.
Wen L, Zheng Y, Wen X, Zhang Y, Zeng W. Increased expression of long noncoding RNA GAS6-AS2 promotes proliferation and inhibits apoptosis of melanoma cells via upregulating GAS6 expression. IUBMB Life. 2019;71(10):1503–14.PubMedCrossRef
238.
Dai C, Liu B, Li S, Hong Y, Si J, Xiong Y, et al. Construction of a circRNA-miRNA-mRNA regulated pathway involved in EGFR-TKI lung adenocarcinoma resistance. Technol Cancer Res Treat. 2021;20:15330338211056808.PubMedPubMedCentralCrossRef
Metadata
Title
Non-coding RNAs as potential therapeutic targets for receptor tyrosine kinase signaling in solid tumors: current status and future directions
Authors
Aysan Moeinafshar
Mohammad Nouri
Nima Shokrollahi
Mahdi Masrour
Amirmohammad Behnam
Sahand Tehrani Fateh
Hossein Sadeghi
Mohammad Miryounesi
Mohammad-Reza Ghasemi
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2024
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-023-03203-2

Other articles of this Issue 1/2024

Cancer Cell International 1/2024 Go to the issue

Research

Low TYROBP expression predicts poor prognosis in multiple myeloma

Research

Spatial and single-cell analyses uncover links between ALKBH1 and tumor-associated macrophages in gastric cancer

Research

Development and validation of a disulfidptosis and disulfide metabolism-related risk index for predicting prognosis in lung adenocarcinoma

Research

Microglia-mediated drug substance transfer promotes chemoresistance in brain tumors: insights from an in vitro co-culture model using GCV/Tk prodrug system

Research

Tumor-matched and unmatched cancer associated fibroblasts exhibit differential effect on proliferation and FMOD and MMP9 gene expression in head and neck squamous cell carcinoma cells when cocultured in spheroids

Research

Integrating bioinformatics and experimental validation to unveil disulfidptosis-related lncRNAs as prognostic biomarker and therapeutic target in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits